Calviri - Immunosignature Technology
Calviri’s Immunosignature (IMS) Technology is universally applicable to the development of diagnostic products. It is based on the recognition that combinatorial peptide sequences provide a richer source of possible antibody binding ligands than proteomic sequences, which are highly redundant. The diversity of antibody specificities is far greater than the diversity of proteomes. The IMS Technology enables an individual’s immense antibody repertoire to be broadly queried and reproducibly measured.
Our IMS approach rests on three key principles:
- IMS engages the full antibody repertoire as disease-induced biomarkers.
- The combinatorially-designed ligands represent a library of mimetic variants of the original epitopes that elicited the antibodies.
- Competitive, parallel binding of antibodies to the library of IMS peptides maximizes the resolution of antibody specificities.
An immunosignature assay provides individual readouts of the many components of a person’s antibody response. This contrasts with a conventional enzyme-linked immunosorbent assay (ELISA) in which all the binding events to the whole virus or antigen in an assay-well are summed into a single readout.